These data support earlier studies showing that use of isCGM in people with type 2 diabetes is associated with lower HbA1c, whether they are treated with multiple daily injections [5, 6], basal insulin only [10, 11] or any glucose-lowering therapies [34]. This evidence concerns the gene INS and type 2 diabetes mellitus.